T-Cell Receptor Peptide Therapeutic Vaccine Technology
IMULAN BioTherapeutics, LLC has started a multi-site placebo controlled trial to evaluate the effects of their T-Cell Receptor (TCR) peptides for feline stomatitis (lymphocytic plasmacytic stomatitis). The TCR Peptides are immune modulating biologics which have been shown to modulate T-helper cell function and Th1/Th2 cytokine profiles. T-helper cells appear to play a central role in feline stomatitis, causing inflammation and inappropriate immune reactions. Preliminary studies in cats have shown significant results in advanced, refractory feline stomatitis. The current studies are confirmatory field trials to obtain approval.
Proceedings on preliminary data available in 2009 Veterinary Dental Forum.
Population: Cats (>1yr of age).
Design: Placebo controlled crossover (all cats get treatment)
Treatment: SQ injections on Day 1 and 14
General Inclusion: Confirmed diagnosis of stomatitis (gingivostomatitis)
General Exclusion: Cats receiving immunosuppressants or any experimental immunotherapeutic.
Special Requirements: Sites able to enroll a minimum of 6 patients
Contact Information: Daniel Gingerich DVM, MS
Chief Scientific Officer - IMULAN BioTherapeutics
email: dgingerich@imulan.com
4221 Mitchell Ave
St. Joseph, MO 65407
www.IMULAN.com